The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
09/06/2012
. If
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
opportunity click
send
me change notification emails
.
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
printed document.
Document Type:
Grants Notice
Funding Opportunity Number:
W81XWH-12-PHTBI-CAP
Opportunity Category:
Discretionary
Posted Date:
Sep 06, 2012
Creation Date:
Sep 06, 2012
Original Closing Date for Applications:
Jan 04, 2013
Current Closing Date for Applications:
Jan 04, 2013
Archive Date:
Feb 03, 2013
Funding Instrument Type:
Cooperative Agreement
Category of Funding Activity:
Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards:
1
Estimated Total Program Funding:
$20,336,000
Award Ceiling:
Award Floor:
CFDA Number(s):
12.420
--
Military Medical Research and Development
Cost Sharing or Matching Requirement:
No
Eligible Applicants
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Additional Information on Eligibility:
Agency Name
Dept. of the Army -- USAMRAA
Description
The primary purpose of the collaborative DoD/VA Consortium will be to improve the health and well-being of Service Members (Active Duty, National Guard, and Reservist) and Veterans, with the most effective diagnostics, prognostics, novel treatments, and rehabilitative strategies to treat acute PTSD and to prevent chronic PTSD. This Consortium is responsive to the findings of the recently released DoD/VA-sponsored Institute of Medicine report focused on “Treatment for Posttraumatic Stress Disorder in Military and Veteran Populations”. Key priorities of this Consortium are elucidation of factors that influence the different trajectories (onset/progression/duration) of PTSD and associated chronic mental and physical sequelae (including depression, anger/aggression, and substance use/abuse, etc.) and identification of measures for determining who is likely to go on to develop chronic PTSD. The Consortium will therefore work to improve prognostics, advance treatments, and mitigate negative long-term consequences associated with traumatic exposure. Focused scientific efforts to understand and treat PTSD have been supported by the DoD and VA extensively. However, to date, treatments have not been fully successful in all individuals. There remains a significant number who do not respond to the currently available treatment regimens, and the question of predicting treatment response remains a priority.
Link to Additional Information
If you have difficulty accessing the full announcement
electronically, please contact:
